Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome | MicrobiomeTrials← Back to trialsNCT04725110
Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome
WITHDRAWNPHASE2INTERVENTIONAL
Trial Details
Start: 2026-01-15Est. Completion: 2030-10-15
Enrollment target: 0 participants Locations- University of Minnesota, Minneapolis, Minnesota, United States
Other microbiome trials you might be interested in
CancerImmunotherapy
The investigators wish to set up a pharmaco-epidemiological cohort within the Hospital Territorial Groups of the Cévenne…
Nîmes, FranceCompleted Sep 16, 2022
Long COVID
This two-year study will evaluate the feasibility and safety of an exercise + cognitive training program to improve neur…
Palo Alto, United StatesEst. completion Dec 31, 2026
Respiratory Tract InfectionSmell DisorderInfluenzaRhinosinusitisCOVID-19DepressionParosmiaHyposomiaNormosomiaAnosmia
Background:
Loss of the sense of smell can seriously affect a person's quality of life. The ability to smell can be dam…
Bethesda, United StatesCompleted Sep 30, 2029